Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 93 EV-to-OCF is 23.50 as of Aug. 24, 2026, which is 31% above its 10-year median of 17.91. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Beximco Pharmaceuticals ranks worse than 58.71% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Beximco Pharmaceuticals's Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $40.54 Mil. Therefore, Beximco Pharmaceuticals's EV-to-OCF for today is 23.50.
The historical rank and industry rank for Beximco Pharmaceuticals's EV-to-OCF or its related term are showing as below:
BXMPY'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.72 Med: 17.91 Max: 55.3
Current: 14.42
During the past 13 years, the highest EV-to-OCF of Beximco Pharmaceuticals was 55.30. The lowest was 6.72. And the median was 17.91.
BXMPY's EV-to-OCF is ranked worse than 58.71% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.68
vs BXMPY: 14.42
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beximco Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Beximco Pharmaceuticals's share price for today is $0.00.
Beximco Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's EV-to-OCF falls into.
Beximco Pharmaceuticals's current Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a EV-to-OCF of 23.50 as of Aug. 24, 2026. This is 31% above median its historical median of 17.91. Over the past decade, Beximco Pharmaceuticals' EV-to-OCF has ranged from 6.72 to 55.30. According to the industry distribution chart, Beximco Pharmaceuticals ranks #590 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is Beximco Pharmaceuticals' EV-to-OCF too high?
Beximco Pharmaceuticals' current EV-to-OCF of 23.50 is 31% above median its 10-year median of 17.91. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 55.30. The Drug Manufacturers industry median EV-to-OCF is 10.68. Beximco Pharmaceuticals' value of 23.50 is 120% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #590 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #590 out of 1005 companies for EV-to-OCF. This places Beximco Pharmaceuticals in the lower half of its industry. The industry median EV-to-OCF is 10.68. Beximco Pharmaceuticals' value of 23.50 is 120% above this benchmark. Historically, Beximco Pharmaceuticals' own EV-to-OCF has ranged from 6.72 to 55.30 over the past decade. While the company's 10-year median is 17.91 vs. the industry median of 10.68, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.68, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current EV-to-OCF of 23.50 is 120% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current EV-to-OCF is 23.50, which is 31% above median its own 10-year median of 17.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EV-to-OCF of 23.50. The current EV-to-OCF is 23.50, which is 31% above median its 10-year median of 17.91 and 120% above the Drug Manufacturers industry median of 10.68. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EV-to-OCF is 23.50 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
